Guo-Hai Zhang

Dr. Guo-Hai Zhang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Molecules
Verified
Journal Article
Open access
PDF file
JLJingjing Li
Jingjing Li
DXDongge Xu
Dongge Xu
LWLingling Wang
Lingling Wang
MZMengyu Zhang
Mengyu Zhang
GZGuo-Hai Zhang
Guo-Hai Zhang
Susu HESusu HE
Susu HE
Glycyrrhizic acid (GA), also known as glycyrrhizin, is a triterpene glycoside isolated from plants of Glycyrrhiza species (licorice). GA possesses a wide range of pharmacological and antiviral activities against enveloped viruses including severe acute respiratory syndrome (SARS) virus. Since the S protein (S) mediates SARS coronavirus 2 (SARS-CoV-2) cell attachment and cell entry, we assayed the GA effect on SARS-CoV-2 infection using an S protein-pseudotyped lentivirus (Lenti-S). GA treatment dose-dependently blocked Lenti-S infection. We showed that incubation of Lenti-S virus, but not the host cells with GA prior to the infection, reduced Lenti-S infection, indicating that GA targeted the virus for infection. Surface plasmon resonance measurement showed that GA interacted with a recombinant S protein and blocked S protein binding to host cells. Autodocking analysis revealed that the S protein has several GA-binding pockets including one at the interaction interface to the receptor angiotensin-converting enzyme 2 (ACE2) and another at the inner side of the receptor-binding domain (RBD) which might impact the close-to-open conformation change of the S protein required for ACE2 interaction. In addition to identifying GA antiviral activity against SARS-CoV-2, the study linked GA antiviral activity to its effect on virus cell binding.

1 November 2014 in Optics & Laser Technology
Verified
Journal Article
Closed access
YZYoujin Zheng
Youjin Zheng
QLQiang Lü
Qiang Lü
JWJialiang Wang
Jialiang Wang
GZGuo-Hai Zhang
Guo-Hai Zhang
YGYang Gao
Yang Gao
Zhanbo LiuZhanbo Liu
Zhanbo Liu

1 May 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JYJing-Mei Yuan
Jing-Mei Yuan
KWKai Wei
Kai Wei
GZGuo-Hai Zhang
Guo-Hai Zhang
NCNan-Ying Chen
Nan-Ying Chen
Xinwei WeiXinwei Wei
Xinwei Wei
GSGui-Fa Su
Gui-Fa Su

1 May 2019 in Biochemical Pharmacology
Verified
Journal Article
Closed access
GZGuo-Hai Zhang
Guo-Hai Zhang
FMFeng'E Ma
Feng'E Ma
LLLiangping Li
Liangping Li
JLJingjing Li
Jingjing Li
PLPingping Li
Pingping Li
ELErguang Li
Erguang Li

12 May 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PLPingping Li
Pingping Li
YZYufei Zhao
Yufei Zhao
MLMinghan Lu
Minghan Lu
CCChengfei Chen
Chengfei Chen
YLYongkun Li
Yongkun Li
GZGuo-Hai Zhang
Guo-Hai Zhang
Polo-like kinase 1 (PLK1) signaling drives tumor malignancy and chemotherapy resistance, which is an unmet clinical need. Recruiting PLK1 to the central spindle during anaphase is necessary for its function in promoting cancer cell proliferation, which is achieved by binding to microtubule-associated protein regulating of cytokinesis (PRC1) located in the spindle. However, the role of PLK1/PRC1 signaling in chemotherapy resistance is unknown. In this study, we identified a small molecule B4 which inhibited PLK1/PRC1 signaling through disrupting the formation of PLK1/PRC1 protein complexes. In the presence of blocking PLK1/PRC1 signaling, enhanced sensitivity of drug-resistant tumors to traditional chemotherapy was found. Suppression of PLK1 activity by B4 inhibited disease progression in allograft models, and combination with cisplatin elicited dramatic regression of drug-resistant tumors. Our findings provide a promising strategy to target the PLK1 signaling cascade and demonstrate a potential modality to enhance sensitivity to chemotherapy in non-small cell lung cancer (NSCLC).

11 September 2024 in Journal of Natural Products
Verified
Journal Article
Closed access
JZJia-Tong Zhou
Jia-Tong Zhou
QWQian Wu
Qian Wu
JZJing-Xian Zhao
Jing-Xian Zhao
LWLiu-Lin Wu
Liu-Lin Wu
XHXian-Hua He
Xian-Hua He
RYRui-Yun Yang
Rui-Yun Yang